

Amendments to the Specification:

Please replace the paragraph beginning at page 8, line 14 with the following amended paragraph:

Fig. 3 is a diagram showing the calibration curve produced with the oxidized HDL obtained in Example 2 of the present invention as a sample, in which the oxidized HDL is prepared by freeze-drying the HDL oxidized with copper and then dissolving the ~~dried~~ dried HDL by a prescribed method.

Please replace the paragraph beginning at page 27, line 1 with the following amended paragraph:

In the seventh aspect of ~~the~~ this invention described above, when the standard substance is not contained in the reagent kit but is still retained on the precondition that it will be substantially used in a kit, the standard substance according to the present invention ought to be recognized as a component element for the reagent kit.

Please replace the paragraph beginning at page 30, line 20 with the following amended paragraph:

Male Balb/c mice not less than 8 weeks old, after administration by intra-abdominal injection of pristane (2,6,10,14-tetramethylpentadecane) with a dose of 0.5 mL/individual were each reared for two weeks. Then, the mice were each administrated to intra-abdominally with a hybridoma cell line FOH1a/DLH3, a cell capable of yielding a required ~~monoclonal~~ monoclonal antibody (Deposit No. FERM BP-7171; J. Biol. Chem. 1994, 269: 15274-15279; and Patent publication JP-A-07-238,098) with a dose of 1×10^6 /individual. 7-14 days later, when the mice each accumulated ascites amply in the abdomen, the ascites was collected from the abdomen by the use of an 18G syringe and centrifuged at 3000 rpm for 10 minutes. The supernatant consequently formed was collected. To this supernatant, an equal amount of PBS (pH 7.4) was added. To the produced mixture, a saturated ammonium sulfate solution equal in amount to the mixture was added dropwise over a period of one hour as kept thoroughly stirred. The resultant mixture was continuously stirred further for one hour and then centrifuged at 3000 rpm for 10 minutes to discard the supernatant and collect the sediment. Further, the sediment

was dissolved in PBS (pH 7.4) containing 0.5 mol/L of NaCl. The produced solution was treated with a Sephadex S-300 column (2.5 cm x 100 cm) (Pharmacia Corp.) equilibrated with PBS (pH 7.4) containing 0.5 mol/L of NaCl to collect a IgM fraction, which was designated as "DLH3 antibody." The concentration of the DLH3 antibody (mg/mL) was determined by measuring a given sample for absorbance at 280 nm in a light path 1 cm in length and dividing the obtained absorbance by 1.3.

Please replace the paragraph beginning at page 35, line 18 with the following amended paragraph:

In the individual wells of a 96F microplate (NALGE NUNC International International K.K.), an anti-human apo-AI mouse monoclonal antibody (Nippon Chemi-con Corp.) solution diluted with a carbonate buffer (pH 9.5) to a concentration of 10 µg/mL was dispensed in a unit volume of 0.1 mL/well and incubated at 4°C for 16 hours. The antibody solution formed in the wells was discarded. The residue in each of the wells was blocked by being incubated together with 350 µL of PBS (pH 7.4) containing 1 (w/v) % of BSA at room temperature for two hours. The blocked antibody solution was washed four times with PBS (pH 7.4) containing 0.05 (v/v) % of Tween20.

Please replace the paragraph beginning at page 39, line 15 with the following amended paragraph:

In the individual wells of a 96F microplate (NALGE NUNC International International K.K.), an anti-human Lp(a) mouse monoclonal antibody (Nippon Chemi-con Corp.) solution diluted with a carbonate buffer (pH 9.5) to a concentration of 10 µg/mL was dispensed in a unit amount of 1 µg/well and incubated at 4°C for 16 hours. The antibody solution formed in the wells was discarded. The residue in each of the wells was blocked by being incubated together with 350 µL of PBS (pH 7.4) containing 1 (w/v) % of BSA at room temperature for two hours. The blocked antibody solution was washed four times with PBS (pH 7.4) containing 0.05 (v/v) % of Tween20.

Please replace the paragraph beginning at page 50, line 11 with the following amended paragraph:

After the preservation for the stated period, the standard freeze-denatured LDLs (1) and (2) and the standard oxidized LDLs (3) and (4) were each measured absorbance ~~at~~ at 492 nm by following the method for determination of oxidized LDL in accordance with the sandwich ELISA method described in Example 1 (4). The oxidized LDL contents in the standard samples were sought from the calibration curve formed in Example 1 (4), based on the absorbance obtained by the measurement ~~above~~ above. The results are shown in Table 3 and Fig. 10.

Please replace the paragraph beginning at page 52, line 21 with the following amended paragraph:

By the method of the present invention, therefore, it has now become possible to produce denatured lipoprotein excelling in stability of preservation, to put it in other wards, exhibiting definite determinations. In addition to the advantage mentioned above, the stabilized lipoprotein which is produced by freeze-drying denatured lipoprotein obtained by performing a process including at least one freezing operation on a solution containing denatured lipoprotein excels not only in stability of preservation but also in stability of preservation after dissolution. The stabilized denatured lipoprotein contemplated by the present invention retains the excellent stability even when it is ~~applyed~~ applied to the form of a solution, i.e. the forms as actual use. This fact makes this stabilized denatured lipoprotein highly advantageous for the sake of determining denatured lipoprotein.